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Purpose: To evaluate myocardial conductivity to understand cardiac 
involvement in patients with mitochondrial disease.
Methods: We performed retrospective study on fifty-seven 
nonspecific mitochondrial encephalopathy patients with no 
clinical cardiac manifestations. The patients were diagnosed 
with mitochondrial respiratory chain complex defects through 
biochemical enzyme assays of muscle tissue. We performed 
standard 12-lead electrocardiography (ECG) on all patients.
Results: ECG abnormalities were observed in 30 patients (52.6%). 
Prolongation of the QTc interval (>440 ms) was seen in 19 patients 
(33.3%), widening of the corrected QRS interval in 15 (26.3%), 
and bundle branch block in four (7.0%). Atrioventricular block, 
premature atrial contraction and premature ventricular contraction 
were seen in two patients each (3.5%) and Wolff-Parkinson-White 
syndrome in one patient (1.8%).
Conclusion: Given this finding, we recommend active screening 
with ECG in patients with mitochondrial disease even in patients 
without obvious cardiac manifestation. 
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Introduction
Mitochondria are the main energy producing cellular 
organelles
1). Mitochondrial disease (MD) is an inherited metabolic 
disorder which generally affects the cellular energy metabolism 
of tissues due to defects in the mitochondrial respiratory chain 
complex (MRC)
2). These MRC defects affect cellular function 
in several of ways
3). The most commonly recognized clinical 
manifestations of MRC defects are related to the neuromuscular 
system. However, MRC defects can affect any organ system in the 
human body, and the clinical symptoms vary greatly depending on 
the organs affected
4, 5).
Cardiovascular involvement has been studied as an important 
prognostic factor in many diseases
6-10). It follows that cardiovascular 
involvement could also be an important prognostic factor in MD
11, 
12). A previous study reported that the prevalence of cardiovascular 
involvement ranked second behind visceral involvement in 
patients with MD
13). Also, Finsterer
14) followed 113 MRC defect 
patients over a ten-year period and found that 40% of the patients 
developed heart disease including cardiomyopathy and heart 
failure. But unfortunately, most of the studies have been made on 
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specific classic mitochondrial syndrome such as mitochondrial 
encephalopathy, lactic acidosis, and stroke like syndrome (MELAS) 
or Kearns-sayre syndrome or with specific mitochondrial DNA 
mutation. Little reports were made concerning cardiac conduction 
in patients with diverse mitochondrial diseases not to mention in 
Korean patients. 
In this study, we analyzed characteristics of cardiac conductivity 
using ECG in patients with nonspecific MD who take higher 
percentage than those with specific types among mitochondrial 
disease population. 
Materials and methods
1. Patients group
We performed a retrospective study on 57 MD patients with 
MRC defect and nonspecific encephalopathy who did not have 
clinical cardiovascular disease manifestations. The patients 
had been previously treated in the Department of Pediatrics of 
Gangnam Severance Hospital from March 2006 to February 
2008. All MRC defect patients were confirmed by biochemical 
enzyme assays of muscle tissue. We excluded the specific 
mitochondrial syndrome and only included patients with MRC 
defect I, the most common type of MRC defect, to increase the 
homogeneity of the study.
We evaluated mitochondrial enzyme function of isolated 
mitochondria collected from muscle tissue using the spec-
trophotometric assay previously described by Rustin et al
15). 
The activities of nicotinamide adenine dinucleotide (NADH), 
coenzyme Q (CoQ) reductase (complex I), succinate-CoQ 
reductase (complex II), succinate-cytochrome c reductase (complex 
II-III), cytochrome c reductase (complex III), cytochrome c oxidase 
(complex IV), oligomycin-sensitive ATPase (complex V) and citrate 
synthase were evaluated and we defined MRC defects as residual 
enzyme activity of less than 20% compared to that of the age-
matched controls. 
2. Electrocardiography
We performed standard 12-lead ECG on all patients and 
recorded amplitude by 1 mV/10 mm and speed by 25 mm/
sec. All patients were in the supine position during the ECGs. 
Cardiologists analyzed all ECGs retrospectively from paper 
printouts. We measured RR and QT intervals in lead II and then 
corrected QT (QTc) by Bazett’s formula, QTc = QT / √RR
16).
The abnormalities on the ECGs were compared with the normal 
reference ranges
7, 17, 18) (Normal PR interval: 90 to 170 ms for 7-15 
years old and 120 to 200 ms for ≥16 years old; Normal QRS 
duration: 40 to 90 ms for 7-15 years and 50 to 100 ms for ≥16 years 
old; Normal QTc: ≤440 ms; Abnormal T wave: QRS-T angle > 
60˚ in limb lead, T wave < 10 % of QRS height or negative T wave 
in leads V4-6).
Results
1. Patient characteristics 
The mean age of MRC defect patients was 4.8±2.6 (mean 
±SD, years) and the gender ratio was 1:19 (Male:Female). 
Regarding clinical manifestations, all 57 patients (100%) 
showed neuromuscular system involvement, all showed 
delayed development and 50 (87.7%) suffered from epilepsy. 
Cardiovascular involvement was detected in 30 patients (52.6%) 
by ECG results. There were five patients (8.8%) with renal system 
involvement, of which four (7.0%) had decreased glomerular 
filtration rate and one (1.8%) had hypercalciuria (random urine 
Calcium/Creatinine ratio >0.2). Hepatobiliary involvement was 
seen in six patients (10.5%). Five (8.8%) patients had abnormal 
liver echogenicity on sonography and four (7.0%) had chronic 
elevation of amino transferase. Ophthalmologic involvement was 
seen in 16 patients (28.1%). Decreased visual acuity was noted in 
nine (15.8%) children and abnormal visual evoked potential in 
12 (21.1%). Auditory involvement in four (7.0%), and endocrine 
involvement in one (1.8%) with hypoparathyroidism (Table 1).
Table 1. Demographic Characteristics of Mitochondrial Disease Patients
Characteristics
Age (mean±SD, years)
Sex (M:F)
Organ involvement (No, %) 
   Neuromuscular
      Developmental delay
      Epilepsy
   Cardiovascular 
      ECG abnormalities 
   Renal 
      Decreased glomerular filtration rate
      Hypercalciuria 
   Hepatobiliary 
      Abnormal liver echogenecity on sonography
      Chronic elevation of aminotransferase  
   Ocular   
      Decreased visual acuity
      Abnormal finding in visual evoked potential
   Auditory
      Abnormal finding in auditory evoked potential
   Endocrinology
      Hypoparathyroidism
4.8±2.6 
26:31
57 (100)
      57 (100)
      50 (87.7)
30 (52.6)
      30 (52.6)
5 (8.8)
        4 (  7.0)
        1 (  1.8)
6 (10.5)
        5 (  8.8)
        4 (  7.0)
16 (28.1)
       9 (15.8)
     12 (21.1)
4 (7.0)
      4 (  7.0)
1 (1.8)
      1 (  1.8)
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2. ECG findings 
ECG abnormalities were observed in 30 patients (52.6%). 
Prolongation of the QTc interval (>440 ms) was seen in 19 patients 
(33.3%), widening of the corrected QRS interval in 15 (26.3%), 
and bundle branch block in four (7.0%). Atrioventricular block, 
premature atrial contraction and premature ventricular contraction 
were seen in two patients each (3.5%). Wolff-Parkinson-White 
syndrome was noted in one patient (1.8%) (Table 2). 
Discussion
In this study, prolongation of QTc was the most frequent 
pathologic finding on ECG. The QT interval reflects the total 
duration of ventricular repolarization and depolarization, and the 
QTc is a known predictor of cardiovascular mortality in patients 
with and without known cardiac disease
18, 19). Prolongation of QTc 
can cause fatal ventricular arrhythmia as a consequence of early 
development of depolarization. Many studies have focused on the 
relationship between QTc prolongation and mortality in a variety 
of diseases. Salles et al
20) studied the relationship between QTc 
prolongation and mortality risk in patients with type 2 diabetes 
mellitus and found that the hazard ratio increased among patients 
with QTc prolongation. Okin et al
21) also found that diabetic 
patients with QTc prolongation had an increased risk of death and 
a five-year mortality of 25.3% compared with 13.9% in individuals 
without QTc prolongation. Based on studies that have shown that 
QTc prolongation is associated with increased mortality, we think 
that it could be used as an indicator for decreased cardiac function 
and possible sudden cardiac death in patients with MD. 
Previous studies of cardiac involvement in MD patients have 
mostly focused on cardiomyopathy
11-13, 22, 23), and the studies that do 
focus on conduction abnormalities have been restricted to Kerns-
Sayre syndrome, which is associated with long QT syndrome
24, 25). 
In this study, we could observe a variety of ECG abnormalities in 
our patients. Up until now, the pathophysiology of cardiovascular 
involvement in MD has been explained by a decrease in adenosine 
triphosphate (ATP) synthesis and damage by reactive oxygen 
species. Defects in ATP synthesis seem to affect both cardiac 
conduction and contraction
12, 22).
Our study of nonspecific mitochondrial encephalopathy patients 
again demonstrated that the heart is the second most frequently 
involved organ behind the neuromuscular system. Since the heart 
is heavily dependent on energy metabolism, it is one of the first 
organs to be affected when there is a defect in MRC
11). There 
have been similar findings in other metabolic disorders. Bonnet 
et al
26) recently found 24 cases of arrhythmias in 107 patients 
with defects in fatty acid oxidation. In those 24 patients, they also 
detected accumulations of long-chain acylcarnitine in fibroblasts. 
These accumulations occurred because the long-chain fatty acid 
transporters could not cross the mitochondrial inner membrane. 
Furthermore, Koisumi et al
27) found that patients with abnormally 
low levels of serum free carnitine had a higher risk of ventricular 
hypertrophy and provided evidence that low carnitine levels could 
induce electromyocardial changes. More extensive studies on 
mitochondrial metabolism are needed as seems to be intimately 
related to those results. 
There are some limitations in this study. Since MD is rare we 
could not perform a prospective study. We did, however, evaluate 
cardiac function in patients with nonspecific mitochondrial 
encephalopathy and not just with a specific mitochondrial 
syndrome, an evaluation which had not yet been done. We found 
that their cardiac conductivity was affected. Because of this 
finding, we strongly recommend active screening and regular 
follow-up of patients with MD using ECG even in patients who 
do not exhibit typical cardiac manifestations. In addition, we think 
that not only screening test on conductivity but also contractility 
using echocardiography would be useful as well. These screening 
techniques will allow for early detection of any abnormalities 
in conductivity or contractility that could potentially lead to 
cardiomyopathy and sudden cardiac death. That being said, further 
study of cardiac involvement in patients with MD is needed to 
explore methods for reducing the risks of cardiomyopathy and 
sudden cardiac death.
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Table 2. The Abnormalities Detected by Electrocardiography in 
Mitochondrial Disease Patients
Abnormalities
QTc prolongation (ms)
QRS widening (ms) 
Bundle branch block
Atrioventricular block 
Premature atrial contraction
Premature ventricular contraction
Wolff-Parkinson-White syndrome
19 (33.3)
15 (26.3)
  4 (  7.0) 
  2 (  3.5)
  2 (  3.5)
  2 (  3.5)
  1 (  1.8)
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